Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers

Table 1

Association between miR-362-5p expression, Sema3A protein expression, and clinicopathologic characteristics in breast cancer tissue array ().

	Total	miR-362-5p expression			Sema3A expression
	()	Negative/weak ()	Moderate/strong ()		Negative/weak ()	Moderate ()	Strong ()
Age
≤50 y	46	22	24	0.9774	13	19	14	0.4822
>50 y	104	50	54		39	34	31
Grade
I+II	74	37	37	0.6507	27	24	23	0.6301
III	65	35	30		19	25	21
T stage
T1	39	24	15	0.0661	9	15	15	0.1875
T2	90	41	49		32	32	26
T3	17	5	12		9	6	2
N stage
N0	78	39	39	0.8396	24	27	27	0.098
N1	38	18	20		14	12	12
N2	19	8	11		9	5	5
N3	13	5	8		4	9	0
AJCC stage
I	24	16	8	0.0703	4	11	9	0.0407
II	82	38	44		28	25	29
III	38	14	24		17	16	5
HER-2
Negative	89	26	63	<0.0001	34	31	24	0.3932
Positive	54	43	11		15	20	19
ER
Negative	78	35	43	0.4765	32	25	21	0.2583
Positive	71	36	35		20	28	23
PR
Negative	91	43	48	0.9981	34	32	25	0.4566
Positive	55	26	29		16	19	20
Types
ER^+ and/or PR^+	79	37	42	0.0002	25	30	24	0.2278
HER-2^+/ER^−/PR^−	27	21	6		6	10	11
HER-2^−/ER^−/PR^−	35	9	26		17	10	8